March 23, 2020 / 12:45 PM / 4 months ago

Intra-Cellular prices schizophrenia drug at $1,320 per month

March 23 (Reuters) - Intra-Cellular Therapies Inc said on Monday its lead drug to treat schizophrenia was now available at U.S. pharmacies for a list price of $1,320 a month.

The U.S. Food and Drug Administration in December approved the drug, Caplyta, as a once-daily dose of 42 mg, which had shown to regulate three neurotransmitter systems linked to severe mental illnesses.

Existing anti-psychotic drugs in the U.S. market include Rexulti from Danish drugmaker H. Lundbeck A/S and Japan's Otsuka Pharmaceutical Co Ltd, Vraylar from Allergan Plc, and Johnson & Johnson's Invega.

The list price for drugs is not necessarily what patients actually pay, as "out-of-pocket" costs vary based on the duration of the treatment and individual healthcare plans. (Reporting by Trisha Roy in Bengaluru; Editing by Shinjini Ganguli)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below